606143-46-8

Basic information

• Product Name: Methyl 6-(4-broMo-2-chlorophenylaMino)-7-fluoro-1H-benzo[d]iMidazole-5-carboxylate
• Synonyms: Methyl 6-(4-broMo-2-chlorophenylaMino)-7-fluoro-1H-benzo[d]iMidazole-5-carboxylate;methyl 5-(4-bromo-2-chlorophenylamino)-4-fluoro-1H-benzo[d]imidazole-6-carboxylate
• CAS NO: 606143-46-8
• Molecular Formula: C₁₅H₁₀BrClFN₃O₂
• Molecular Weight: 398.6142032
• Mol File: 606143-46-8.mol

Chemical Properties

• Boiling Point: 539.0±50.0 °C(Predicted)
• Appearance: /
• Density: 1.722±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 10.14±0.30(Predicted)
• CAS DataBase Reference: Methyl 6-(4-broMo-2-chlorophenylaMino)-7-fluoro-1H-benzo[d]iMidazole-5-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 6-(4-broMo-2-chlorophenylaMino)-7-fluoro-1H-benzo[d]iMidazole-5-carboxylate(606143-46-8)
• EPA Substance Registry System: Methyl 6-(4-broMo-2-chlorophenylaMino)-7-fluoro-1H-benzo[d]iMidazole-5-carboxylate(606143-46-8)

Safety Data

• Hazardous Substances Data: 606143-46-8(Hazardous Substances Data)

Usage

Uses

Used in Chemical Research:
Methyl 6-(4-bromo-2-chlorophenylamino)-7-fluoro-1H-benzo[d]imidazole-5-carboxylate is used as a research compound for exploring its chemical properties and potential reactions due to its unique structure and functional groups.
Used in Pharmaceutical Development:
In the pharmaceutical industry, Methyl 6-(4-bromo-2-chlorophenylamino)-7-fluoro-1H-benzo[d]imidazole-5-carboxylate is used as a starting material or intermediate in the synthesis of new drug candidates, leveraging its complex structure for potential therapeutic applications.

Upstream product

• 606093-59-8 7-Fluoro-6-phenylamino-3H-benzoimidazole-5-carboxylic acid methyl ester 
• 606144-42-7 4,5-diamino-3-fluoro-2-phenylamino-benzoic acid methyl ester 
• 606093-58-7 4-Amino-3-fluoro-5-nitro-2-phenylamino-benzoic acid methyl ester 
• 284030-58-6 4-Amino-2,3-difluoro-5-nitro-benzoic acid methyl ester 
• 61079-72-9 2,3,4,-trifluorobenzoic acid 
• 284030-57-5 4-amino-2,3-difluoro-5-nitro-benzoic acid 
• 197520-71-1 2,3,4-trifluoro-5-nitro-benzoic acid 

Downstream Products

• 606144-11-0 6-(4-Bromo-2-chloro-phenylamino)-3-(2-tert-butoxycarbonyl-ethyl)-7-fluoro-3H-benzoimidazole-5-carboxylic acid methyl ester 
• 606144-04-1 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-1-methyl-1H-benzimidazole-6-carboxylic acid 
• 606144-02-9 methyl 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-1-methyl-1H-benzimidazole-6-carboxylate 
• 606144-01-8 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazole-5-carboxylic acid 
• 606144-03-0 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-1-methyl-1H-benzoimidazole-5-carboxylic acid methyl ester 

Relevant articles and documents

Substituted benzimidazole compound and composition with compound

The invention provides a substituted benzimidazole compound and a composition with the compound. The substituted benzimidazole compound is a compound of formula (I) as shown in the specification, or apharmaceutically acceptable salt, prodrug, aquo-complex or solvent compound, polycrystalline type compound, stereisomer or isotope variant of the compound. The compound provided by the invention canbe adopted to treat and/or prevent related diseases caused by MEK (Methyl Ethyl Ketone), such as excessive proliferative diseases, pancreatitis, kidney illness, blastocyte cell transplantation and angiogenesis or angiopoiesis related diseases.

NOVEL HYDROGEN SULFATE SALT

The present invention relates to Compound 1 hydrogen sulfate salt and solvates, crystalline forms and amorphous forms thereof, and to processes for their preparation. Compound I

N3 alkylated benzimidazole derivatives as MEK inhibitors

Disclosed are compounds of the formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.